執行版證券購買協議本證券購買協議(“本協議”)的日期為2024年1月31日，由特拉華州的一家公司Kiora製藥公司(“本公司”)與本協議簽名頁上確定的每一位買方(包括其繼任者和受讓人、一位“買方”和統稱為“買方”)簽署。鑑於在本協議所載條款及條件的規限下，以及根據1933年證券法(經修訂)第4(A)(2)節及/或其下D條所載經修訂證券法(“證券法”)第5節註冊要求的豁免，本公司希望向每名買方發行及出售，而每名買方個別而非共同地希望向本公司購買本協議中更全面描述的本公司證券。因此，現在，考慮到本協議中包含的相互契約，並出於其他良好和有價值的代價，公司和每一位買方同意如下：第1節定義1.1定義。除本協議中其他地方定義的術語外，就本協議的所有目的而言，下列術語具有第1.1節中規定的含義：“行動”應具有第3.1(J)節中賦予該術語的含義。“關聯公司”是指任何直接或間接通過一個或多箇中介機構控制或由某人控制或與其共同控制的人，該等術語在證券法下的規則405中使用和解釋。“公司註冊證書修正案”應具有3.1(F)節中賦予該術語的含義。“BHCA”應具有3.1(Mm)節中賦予該術語的含義。“買入價格”應具有4.1(D)節中賦予該術語的含義。“董事會”是指公司的董事會。“營業日”是指除星期六、星期日或法律授權或要求紐約市商業銀行繼續關閉的其他日子外的任何日子；但是，為澄清起見，只要紐約市商業銀行的電子資金轉賬系統(包括電匯轉賬)在這一天對客户開放，商業銀行不應被視為獲得授權或被法律要求繼續關閉，只要在這一天，紐約商業銀行的電子資金轉賬系統(包括電匯系統)通常對客户開放，則不應因“待在家裏”、“就地避難”、“非必要僱員”或任何其他類似命令或限制或因任何政府當局的指示關閉任何實體分行而被視為獲得授權或法律要求商業銀行繼續關閉。“成交”是指根據第2.1節的規定，證券買賣的成交。“成交日期”是指所有交易文件已由適用各方簽署並交付的交易日，以及(I)買方支付認購金額的義務和(Ii)公司交付證券的義務在任何情況下均已滿足或免除的所有條件，但在任何情況下，不得遲於本協議日期後的第二(2)個交易日。“委員會”是指美國證券交易委員會。“普通股”是指公司的普通股，每股票面價值0.01美元，以及此類證券今後可能被重新分類或變更的任何其他類別的證券。

2“普通股等價物”指公司或附屬公司的任何證券，使其持有人有權隨時收購普通股，包括但不限於任何債務、優先股、權利、期權、認股權證或其他可在任何時間轉換為普通股或可行使或交換，或以其他方式使持有人有權獲得普通股的工具。“普通權證股份”是指行使普通權證後可發行的普通股股份。“普通權證”是指A部分權證和B部分權證。“公司法律顧問”指Burns&Levinson LLP，其辦事處位於馬薩諸塞州波士頓高街125號，郵編02110-1624。“披露明細表”是指在此同時交付的公司披露明細表。“披露時間”是指，(I)如果本協議是在非交易日或上午9：00之後簽署的。(紐約市時間)和任何交易日午夜前(紐約市時間)上午9：01。(Ii)如果本協議是在午夜(紐約市時間)至上午9：00之間簽署的，則在緊接本協議日期之後的交易日(紐約市時間)，除非配售代理另有指示，否則將於較早時間簽署。(紐約市時間)在任何交易日，不遲於上午9：01(紐約市時間)，除非安置代理另有指示將時間提前。“取消資格事件”應具有3.1(QQ)節中賦予該術語的含義。“DVP”應具有第2.1節中賦予該術語的含義。“生效日期”應具有4.1(B)節中賦予該術語的含義。“有效期”應具有第4.15(A)節中賦予該術語的含義。“環境法”應具有3.1(M)節中賦予該術語的含義。“評估日期”應具有第3.1節(S)中賦予該術語的含義。“事件”應具有第4.15(B)節中賦予該術語的含義。“交易法”係指修訂後的1934年證券交易法及其頒佈的規則和條例。“豁免發行”係指(A)普通股、限制性股票單位或期權的股份，包括受限股票單位或期權的基礎普通股，根據董事會多數非僱員成員或為向公司提供服務而設立的非僱員董事委員會的多數成員為此目的而正式採用的任何股票或期權計劃或安排，向公司的僱員、高級管理人員、顧問或董事發行。(B)行使或交換或轉換根據本協議發行的任何證券和/或其他可行使、可交換或可轉換為在本協議日期已發行並尚未發行的普通股的證券，但自本協議日期以來，該等證券並未經修訂以增加該等證券的數目或降低該等證券的行使價、交換價或轉換價(如美國證券交易委員會報告所披露的與其中所載的股票拆分或合併或反攤薄條文有關的除外)或延長該等證券的期限，及(C)根據合併、收購或戰略交易而發行的證券，包括經本公司多數無利害關係董事批准的與第三方的許可協議，但該等證券須作為“受限制證券”(定義見第144條)發行，並無登記權利要求或準許在本條例第4.14(A)節的禁止期內提交任何與此有關的登記聲明，並進一步規定，任何此類發行只可向本身或透過其附屬公司本身或透過其附屬公司的個人(或某人的股權持有人)發行

3與本公司的業務協同，本公司在任何資金投資之外獲得利益，但不包括本公司發行證券的主要目的是籌集資本或向以證券投資為主要業務的實體發行證券的交易。“反海外腐敗法”係指修訂後的1977年《反海外腐敗法》。“FDA”應具有3.1(HH)節中賦予該術語的含義。“FDCA”應具有3.1(Hh)節中賦予該術語的含義。“美聯儲”應具有3.1(Mm)節中賦予該術語的含義。“公認會計原則”是指美國公認的會計原則。“危險材料”應具有3.1(M)節中賦予該術語的含義。“負債”應具有3.1(Aa)節中賦予該術語的含義。“知識產權”應具有3.1(P)節中賦予該術語的含義。“發行人”應具有3.1(QQ)節中賦予該術語的含義。“IT系統和數據”應具有3.1(JJ)節中賦予該術語的含義。“圖例移除日期”應具有第4.1(C)節中賦予該術語的含義。“留置權”是指留置權、抵押權、質權、擔保物權、產權負擔、優先購買權或其他限制。“重大不利影響”應具有3.1(B)節中賦予該術語的含義。“材料許可”應具有3.1(N)節中賦予該術語的含義。“洗錢法”應具有3.1(Nn)節中賦予此類術語的含義。“OFAC”應具有3.1(Kk)節中賦予該術語的含義。“每股收購價”相當於0.5524美元，需要對股票的反向和正向拆分、股票分紅、股票合併以及在本協議發佈之日和截止日期之間發生的普通股的其他類似交易進行調整。“個人”是指個人或公司、合夥企業、信託、法人或非法人團體、合資企業、有限責任公司、股份公司、政府(或其機關或分支機構)或其他任何類型的實體。“藥品”應具有3.1(Hh)節中賦予該術語的含義。“安置代理”指Maxim Group LLC。“安置代理律師”指Thompson Hine LLP，其辦公室位於紐約麥迪遜大道300號27層，郵編：10017-6232。預出資認股權證股份，是指預出資認股權證行使後可發行的普通股股份。

4“預資資權證”是指根據本協議第2.2(A)節在收盤時交付給買方的預資金權證，該預資資權證應可立即行使，並在全部行使時失效，實質上如本協議附件A所示。“程序”是指訴訟、索賠、訴訟、調查或程序(包括但不限於非正式調查或部分程序，如書面陳述)，無論是開始的還是受到威脅的。“買方”應具有第4.8節中賦予該術語的含義。“可註冊證券”應具有第4.15(A)節中賦予該術語的含義。“註冊聲明”應具有第4.15(A)節中賦予該術語的含義。“所需批准”應具有3.1(E)節中賦予該術語的含義。“第144條規則”係指證監會根據證券法頒佈的第144條規則，該規則可不時修訂或解釋，或證監會此後通過的任何類似規則或規章，其目的和效力與該規則基本相同。“規則424”是指證監會根據《證券法》頒佈的規則424，該規則可不時修改或解釋，或證監會此後通過的具有與該規則基本相同的目的和效力的任何類似規則或條例。“美國證券交易委員會報告”應具有3.1(H)節中賦予該術語的含義。“證券”是指股份、普通權證和預融資權證。“證券法”係指修訂後的1933年證券法及其頒佈的規則和條例。“股東批准”應具有第4.16節中賦予該術語的含義。“股東批准日期”是指收到股東批准並被視為生效的日期。“股份”是指根據本協議向每位買方發行或可發行的普通股股份。“賣空”是指根據交易法，SHO規則200中定義的所有“賣空”(但不應被視為包括尋找和/或借入普通股)。“標準結算期”應具有4.1(C)節中賦予該術語的含義。“認購金額”對每一買方來説，是指在本協議簽字頁和“認購金額”標題旁的“認購金額”標題下，按買方姓名在本協議簽字頁下方指定的、以美元和立即可用資金支付的根據本協議購買的證券的總金額(如果適用，減去買方對預資金權證的總行使價，該金額應在行使預資金權證時以現金支付)。“附屬公司”指附表3.1(A)所載本公司的任何附屬公司，在適用的情況下，亦包括本公司在本條例生效日期後成立或收購的任何直接或間接附屬公司。“交易日”是指主力交易市場開放交易的日子。“交易市場”是指普通股在有關日期上市或報價交易的下列任何市場或交易所：紐約證券交易所美國市場、納斯達克資本市場、納斯達克全球

5市場、納斯達克全球精選市場或紐約證券交易所(或上述任何交易所的任何繼承者)。“A批認股權證”是指根據本協議第2.2(A)節在成交時向買方交付的A批普通股認購權證，實質上以本協議附件B的形式交付。“B批認股權證”是指根據本協議第2.2(A)節並基本上以附件C的形式在成交時交付給買方的B批普通股認購權證。“交易文件”係指本協議、授權書、本協議的所有證物和明細表以及與本協議項下預期的交易相關而簽署的任何其他文件或協議。“轉讓代理”是指VStock Transfer，LLC，本公司目前的轉讓代理，辦事處位於紐約11598伍德米爾拉斐特廣場18號，以及本公司的任何後續轉讓代理。“可變利率交易”應具有第4.14(B)節中賦予該術語的含義。“VWAP”指在任何日期，由下列適用條款中的第一項確定的價格：(A)如果普通股隨後在交易市場上市或報價，則為彭博新聞社報道的普通股隨後上市或報價的交易市場(或之前最近的日期)普通股的每日成交量加權平均價(根據交易日上午9：30起計算)。(紐約市時間)至下午4：02(紐約時間))，(B)如果OTCQB創業板市場(“OTCQB”)或OTCQX最佳市場(“OTCQX”)不是交易市場，普通股在OTCQB或OTCQX(以適用者為準)該日期(或最近的前一個日期)的成交量加權平均價格；(C)如果普通股當時沒有在OTCQB或OTCQX上市或報價，並且普通股的價格隨後在粉色公開市場(或繼承其報告價格職能的類似機構或機構)上報告，則如此報告的普通股的最新每股投標價格或(D)在所有其他情況下，由當時尚未償還且本公司合理接受的證券的大多數購買者真誠選擇的獨立評估師所確定的普通股股份的公平市場價值，其費用和支出應由本公司支付。“認股權證股份”統稱為普通權證股份和預先出資的認股權證股份。“認股權證”統稱為普通認股權證和預先出資的認股權證。第二節.購銷2.1成交。在成交日期，根據本文所述條款並在符合條件的情況下，公司同意出售，而購買者分別而不是共同同意購買根據第2.2(A)節確定的總額高達4500萬美元的證券；然而，只要買方全權酌情決定該買方(連同該買方的聯屬公司，以及連同該買方或任何該買方的聯屬公司作為一個團體行事的任何人士)將實益擁有超過實益擁有權限額的股份，或按買方的其他選擇，該買方可選擇購買預籌資權證以代替購買股份。“實益所有權限額”應為在截止日期證券發行生效後立即發行的普通股數量的4.99%(或在買方選擇成交時，為9.99%)。每名買方的認購金額應可用於與公司或其指定人進行貨到付款(DVP)結算。本公司應向每位買方交付其各自的證券，本公司和每位買方應在成交時交付第2.2節規定的其他項目。在滿足第2.2節和第2.3節規定的公約和條件後，應通過電子傳輸結束文件的方式遠程進行結束。除非配售代理另有指示，股份的交收將通過DVP進行(即在成交日期，公司應發行登記在買方姓名和地址中並由轉讓代理直接釋放到每個買方指定的配售代理的賬户(S)的股份；在收到該等股份後，配售代理應立即以電子方式將該等股份交付給適用的買方，並且

6配售代理人（或其結算公司）以電匯方式向本公司支付。 儘管有上述規定，對於在截止日期下午12：00（紐約市時間）或之前交付的任何行使通知（定義見預付款認股權證），該通知可在本協議簽署後的任何時間交付，公司同意在截止日期下午4：00（紐約市時間）之前交付受該通知約束的預付款認股權證股份，且截止日期應為認股權證股份交付日期（定義見預付款認股權證）。2.2是的。(a)在交割日當天或之前，公司應向每位買方交付或促使其交付以下文件：（i）由公司正式簽署的本協議;（ii）公司的電匯指示，以公司信箋為抬頭，並由公司首席執行官或首席財務官簽署;（iii）向過户代理髮出的不可撤銷的指示副本，指示過户代理通過證明與該等股份數目相等的股份數目的證書或入賬聲明，買方的認購金額除以每股購買價格，以買方的名義登記;以及（iv）公司法律顧問的法律意見，其形式和內容為配售代理和買方合理接受;（v）以該買方的名義登記的A批普通認股權證，用於購買該買方所列的最多數量的普通股，（vi）以該買方的名義登記的B批普通認股權證，以購買該買方的簽名頁所列的最多數量的普通股，行使價等於0.6076美元，可在其中進行調整;及（vii）就根據第2.1條的每名預付款認股權證的買方而言，以買方名義登記的預付款認股權證，用於購買最多等於（A）買方認購金額除以每股購買價與（B）以其他方式發行給該買方的股份數量，該數量將導致該買方對普通股股份的實益擁有權超過實益擁有權限制，行使價等於每股0.0001美元，並可在其中進行調整。(b)在交割日當天或之前，各買方應向公司交付或促使公司交付以下文件：（i）由買方正式簽署的本協議;以及（ii）買方的認購金額，該金額應可用於與公司或其指定人進行DVP結算。2.3關閉條件。(a)本公司在本協議項下與交割有關的義務須符合以下條件：（i）在交割日，陳述或保證在所有重大方面（或在所有方面，陳述或保證因重大性或重大不利影響而合格）的準確性

7及本協議所載買方的保證(除非截至某一特定日期，則應在該日期準確)；(Ii)每個買方在截止日期或之前必須履行的所有義務、契諾和協議應已履行；以及(Iii)每個買方交付本協議第2.2(B)節規定的物品。(B)買方在本協議項下與結案有關的各項義務須符合下列條件：(I)本協議所載本公司的陳述和保證在作出時和在結案日期在所有重要方面(或在陳述或保證因重大或重大不利影響而受各方面限制的範圍內)均屬準確(除非該等陳述和保證在該日期是準確的)；(Ii)本公司在結案日期或之前須履行的所有義務、契諾和協議均已履行；(Iii)公司交付本協議第2.2(A)條規定的項目；(Iv)自本協議之日起，對公司不應產生任何重大不利影響；(V)公司已終止與林肯公園資本基金有限責任公司的現有股權信用額度；(Vi)從本協議之日起至截止日期，普通股的交易不應被證監會或任何交易市場暫停，在截止日期之前的任何時間，彭博資訊所報告的一般證券的交易不應被暫停或限制，也不應對通過該服務或任何交易市場報告的交易的證券設定最低價格，美國或紐約州當局也不應宣佈銀行暫停交易，也不應發生任何重大的敵對行動或其他國家或國際災難的影響，或任何金融市場的任何重大不利變化，而在每一種情況下，根據買方的合理判斷，在收盤時購買該證券是不切實可行或不可取的。第3節陳述和保證3.1公司的陳述和保證。除《披露明細表》中規定的情況外，披露明細表應被視為本協議的一部分，並應在披露明細表的相應章節中包含的披露範圍內限定任何陳述或以其他方式作出的任何陳述和擔保，公司特此向每位買方作出以下陳述和保證：(A)子公司。本公司的所有直接及間接附屬公司載於附表3.1(A)。本公司直接或間接擁有每間附屬公司的所有股本或其他股權，且無任何留置權，而每間附屬公司的所有已發行及已發行股本均為有效發行、繳足股款、免評税及無優先認購或購買證券的類似權利。(B)組織和資格。本公司及各附屬公司均為正式註冊成立或以其他方式組織、有效存在及根據其註冊成立或組織所在司法管轄區的法律信譽良好的實體，並具有擁有及使用其財產及資產以及按目前進行的方式經營其業務所需的權力及授權，但如未能具備上述資格或信譽，則屬例外。

8案件可能、不可能或不可能合理地預期會造成實質性的不利影響。本公司或任何附屬公司均未違反或違反其各自的證書或公司章程、章程、經營協議或其他組織或章程文件的任何規定。本公司及其附屬公司中的每一家均具備開展業務的正式資格，並且在每個司法管轄區內作為外國公司或其他實體具有良好的信譽，而在每個司法管轄區內，所進行的業務或其擁有的財產的性質使此類資格是必要的，但如未能具備上述資格或信譽(視屬何情況而定)不可能或合理地預期會導致：(I)對任何交易文件的合法性、有效性或可執行性產生重大不利影響；(Ii)對本公司及其附屬公司的營運、資產、業務、前景或狀況(財務或其他方面)的結果產生重大不利影響；或(Iii)對本公司在任何交易文件下及時履行其責任的能力造成重大不利影響(第(I)、(Ii)或(Iii)項中的任何一項，即“重大不利影響”)，且並無在任何該等司法管轄區提起撤銷、限制或限制或尋求撤銷、限制或削減該等權力及授權或資格的訴訟。(C)授權；執行。本公司擁有必要的公司權力及授權，以訂立及完成本協議及其他各項交易文件所擬進行的交易，並以其他方式履行其在本協議及本協議項下的義務。本公司簽署及交付本協議及其他每份交易文件，以及完成擬在此進行的交易，已獲本公司採取一切必要行動正式授權，而本公司、董事會或本公司股東就本協議及其他交易文件所採取的進一步行動，除與所需批准有關外，並不需要採取任何其他行動。本協議及其所屬的每一份其他交易文件已由本公司正式簽署(或在交付時)，當按照本協議和本協議的條款交付時，將構成本公司根據其條款可對本公司強制執行的有效和具有約束力的義務，但以下情況除外：(I)受一般衡平原則和適用的破產、破產、重組、暫停和其他一般適用法律的限制，這些法律一般影響債權人權利的執行；(Ii)受有關具體履行情況的法律的限制；強制令救濟或其他衡平法補救辦法，以及(3)賠償和分擔規定可能受到適用法律的限制。(D)沒有衝突。本公司簽署、交付和履行本協議及其參與的其他交易文件、發行和出售證券以及完成擬進行的交易，不會也不會(I)與本公司或任何子公司的證書或公司章程、章程、經營協議或其他組織或章程文件中的任何規定相沖突或相違反，或(Ii)與下列條款相沖突或構成違約(或在通知或時間流逝後或兩者均為違約的情況)，導致對本公司或任何附屬公司的任何財產或資產產生任何留置權，或給予他人終止、修訂、反攤薄或類似調整的任何權利，加速或取消(不論是否發出通知，時間過去或兩者兼而有之)任何協議、信貸安排、債務或其他文書(證明公司或附屬公司的債務或其他方面)或公司或任何附屬公司的任何財產或資產受其約束或影響的其他諒解；或(Iii)經所需批准，與任何法律、規則、法規、任何法院或政府機關的命令、判決、禁令、法令或其他限制，使公司或任何子公司的任何財產或資產受到約束或影響；但第(Ii)及(Iii)款中的每一項不可能產生或合理地預期不會產生重大不利影響的情況除外。(E)提交、同意和批准。本公司無需獲得任何同意、放棄、授權或命令，向任何法院或其他聯邦、州、地方或其他政府當局或其他人士發出任何通知，或向任何其他人士提交任何與本公司簽署、交付和履行交易文件有關的備案或登記，但以下情況除外：(I)根據本協議第4.4條規定的備案；(Ii)就證券的發行和銷售以及股票和認股權證的上市向每個適用的交易市場發出通知和/或申請(S)，以按照本協議要求的時間和方式在其上進行交易。(Iii)向證監會提交表格D及根據適用的州證券法須提交的文件，以及(Iv)股東批准(統稱為“所需批准”)。(F)證券的發行；登記。股份及認股權證股份已獲正式授權，並於根據適用的交易文件發行及支付時，將獲有效發行、足額發行、

9除交易文件中規定的轉讓限制外，公司施加的所有留置權均為已支付且不可評估、免費且無任何留置權。認股權證經正式授權，根據本協議發行時，將有效發行，除交易文件中規定的轉讓限制外，沒有任何留置權。本公司目前並無足夠數量的正式授權普通股股份可供儲備，以履行其根據本協議條款發行普通權證的義務，並將盡其最大努力促使其法定股本增加，以便於股東批准日期後不遲於兩(2)個工作日修訂其現行有效的經修訂及重述的公司註冊證書(“公司註冊證書修訂”)，以發行普通權證。(G)大寫。本公司於本公告日期之資本總額載於附表3.1(G)，該附表3.1(G)亦應包括據本公司所知，僅根據聯營公司根據條例第13D條及交易所法令第16條審核申報文件而於本公司於本公告日期由本公司聯營公司實益擁有並登記在案之普通股股份數目。除根據本公司股票期權計劃行使僱員購股權、根據本公司僱員購股計劃向僱員發行普通股及根據交易所法令根據最近提交定期報告日期轉換及/或行使已發行普通股等價物外，本公司自最近根據交易所法案提交定期報告以來，並無發行任何股本。除附表3.1(G)所載及因買賣證券而產生外，並無任何尚未行使的購股權、認股權證、認股權證認購、催繳或任何性質的承諾，或可轉換為或可行使或可交換的任何普通股股份或任何附屬公司的股本，或給予任何人士任何權利認購或收購任何普通股或任何附屬公司的股本的合約、承諾、諒解或安排，或本公司或任何附屬公司根據或可能根據該等合約、承諾、諒解或安排發行額外普通股或普通股等價物或任何附屬公司的股本。該等證券的發行及出售將不會令本公司或任何附屬公司有責任向任何人士(買方除外)發行普通股或其他證券，亦不會導致任何持有本公司證券的人士有權調整任何該等證券項下的行使、轉換、交換或重置價格。本公司或任何附屬公司並無未償還證券或票據，當中並無任何條文規定於本公司或任何附屬公司發行證券時調整該等證券或票據的行使、轉換、交換或重置價格。本公司或任何附屬公司並無任何未償還證券或票據載有任何贖回或類似條文，亦無任何合約、承諾、諒解或安排使本公司或任何附屬公司有義務或可能根據該等合約、承諾、諒解或安排贖回本公司或任何附屬公司的證券。本公司並無任何股份增值權或“影子股份”計劃或協議或任何類似計劃或協議。除必要的批准外，證券的發行和銷售不需要任何股東、董事會或其他人的進一步批准或授權。除附表3.1(G)所載者外，並無任何股東協議、投票協議或其他類似協議涉及本公司為訂約方的本公司股本，或據本公司所知，本公司任何股東之間或之間並無任何股東協議、投票協議或其他類似協議。(H)美國證券交易委員會報告；財務報表。除美國證券交易委員會報告中披露的外，本公司已提交根據證券法和交易法規定本公司必須提交的所有報告、時間表、表格、聲明和其他文件，包括根據證券法和交易法第13(A)或15(D)節，在本報告日期前兩年(或法律或法規要求本公司提交該等材料的較短期限)(上述材料，包括通過引用併入其中的證據和文件)，在此統稱為“美國證券交易委員會報告”)或已收到該等備案時間的有效延展，且已在任何該等延展期滿前提交任何該等美國證券交易委員會報告。截至各自日期，美國證券交易委員會報告在所有重大方面均符合證券法和交易法(視具體情況而定)的要求，且所有美國證券交易委員會報告在提交時均未包含對重大事實的任何不真實陳述，或遺漏陳述其中所需陳述的重大事實，或根據報告所述情況而遺漏陳述所需陳述的重大事實，而不具誤導性。本公司從來不是受證券法第144(I)條約束的發行人。美國證券交易委員會報告所載本公司的財務報表在所有重要方面均符合適用的會計要求以及證監會的相關細則和條例

10與提交申請時的效力相同。該等財務報表乃根據公認會計原則編制，但該等財務報表或附註另有規定者除外，且未經審核財務報表不得包含公認會計準則所要求的所有附註，並在各重大方面公平地列示本公司及其綜合附屬公司於其日期及截至該日期的財務狀況，以及截至該日止期間的經營業績及現金流量，但如屬未經審核報表，則須作出正常的、非重大的年終審核調整。(I)重大變化；未披露的事件、負債或發展。除附表3.1(I)所述外，自本公司向證監會提交最新財務報表之日起，(I)並無已發生或可合理預期會導致重大不利影響的事件、發生或發展，(Ii)除(A)根據以往慣例在正常業務過程中發生的貿易應付款項及應計開支及(B)根據公認會計原則須在本公司財務報表中反映或在向證監會提交的文件中披露的負債外，本公司並無產生任何負債(或有或有負債)，(Iii)本公司並無改變其會計方法；(Iv)本公司並無宣佈或向其股東派發任何股息或現金或其他財產，或購買、贖回或訂立任何協議以購買或贖回其股本中的任何股份；及(V)本公司並無向任何高級職員、董事或聯屬公司發行任何股本證券，除非是根據現有的本公司購股權計劃。本公司沒有向委員會提出任何保密處理信息的請求。除本協議預期或附表3.1(I)所述的證券發行外，本公司或其附屬公司或其各自業務、前景、物業、營運、資產或財務狀況的任何事件、責任、事實、情況、發生或發展並無發生或存在，或合理預期將會發生或存在，而根據適用證券法，本公司於作出或被視為作出陳述時，並無任何事件、責任、事實、情況、發生或發展在作出陳述之日前至少一(1)個交易日尚未公開披露。(J)訴訟。除附表3.1(J)所述外，在任何法院、仲裁員、政府或行政機構或監管機構(聯邦、州、縣、地方或外國)面前或由任何法院、仲裁員、政府或行政機構或監管機構(聯邦、州、縣、地方或外國)進行的任何訴訟、訴訟、查詢、違規通知、法律程序或調查，或據本公司所知，任何針對或影響本公司、任何附屬公司或其各自財產的訴訟、訴訟、查詢、通知、法律程序或調查(統稱為“行動”)均不存在。附表3.1(J)、(I)對任何交易文件或證券的合法性、有效性或可執行性造成不利影響或提出質疑，或(Ii)如有不利決定，可能或合理地預期會導致重大不利影響。本公司或其任何子公司，或董事的任何高管，都不是或曾經是任何涉及違反聯邦或州證券法或根據聯邦或州證券法承擔責任的索賠或違反受託責任的索賠的訴訟對象。據本公司所知，證監會並無、且據本公司所知，並無任何涉及本公司或任何現任或前任董事或本公司高管的調查。證監會並無發出任何停止令或其他命令，暫停本公司或任何附屬公司根據《交易法》或《證券法》提交的任何註冊聲明的效力。(K)勞資關係。本公司並不存在任何勞資糾紛，或據本公司所知，有關本公司任何員工的勞資糾紛迫在眉睫，而該等糾紛可合理地預期會導致重大不利影響。本公司或其附屬公司的任何僱員均不是與該僱員與本公司或該附屬公司的關係有關的工會的成員，本公司或其任何附屬公司均不是集體談判協議的一方，本公司及其附屬公司相信其與其僱員的關係良好。據本公司所知，本公司或任何附屬公司的任何行政人員並無或現時預期不會違反任何僱傭合約、保密、披露或專有資料協議或競業禁止協議、或任何其他合約或協議或任何有利於任何第三方的限制性契諾的任何重大條款，而繼續聘用該等行政人員並不會令本公司或其任何附屬公司就任何上述事宜承擔任何責任。本公司及其子公司遵守與僱傭和僱傭慣例、僱傭條款和條件以及工資和工時有關的所有適用的美國聯邦、州、地方和外國法律和法規，但未能遵守的情況除外，無論是個別遵守還是總體遵守，都不會產生重大不利影響。(L)合規。本公司或任何附屬公司：(I)根據或違反(且未發生任何事件)違約，而該等事件並未在通知或時間流逝或兩者兼而有之的情況下被放棄，會導致

11本公司或其任何附屬公司)，亦未收到有關其根據或違反任何契約、貸款或信貸協議或任何其他協議或文書(不論是否已放棄該違約或違規行為)、(Ii)違反任何法院、仲裁員或其他政府當局的任何判決、法令或命令，或(Iii)違反或曾經違反任何政府當局的任何法規、規則、條例或規定的索賠通知，包括但不限於所有外國，與税收、環境保護、職業健康和安全、產品質量和安全以及就業和勞工事務有關的聯邦、州和地方法律，除非在每一種情況下都不會或合理地預期會造成實質性的不利影響。(M)環境法。本公司及其子公司(I)遵守與污染或保護人類健康或環境(包括環境空氣、地表水、地下水、地面或地下地層)有關的所有聯邦、州、地方和外國法律，包括與向環境排放、排放、釋放或威脅釋放化學品、污染物、污染物或有毒或危險物質或廢物(統稱為“危險材料”)有關的法律，或與製造、加工、分配、使用、處理、儲存、處置、運輸或處理危險材料有關的法律，以及所有授權、法規、法令、要求、或要求根據其發佈、登記、頒佈或批准的信件、禁令、判決、許可證、通知或通知信件、命令、許可證、計劃或條例(“環境法”)；(Ii)已獲得適用環境法要求其開展各自業務所需的所有許可證、許可證或其他批准；及(Iii)遵守任何該等許可證、許可證或批准的所有條款及條件，而在第(I)、(Ii)及(Iii)項中，每項條款均可合理預期未能遵守該等條款及條件會對個別或整體產生重大不利影響。(N)監管許可證。本公司及其附屬公司擁有開展美國證券交易委員會報告所述各自業務所需的由適當的聯邦、州、地方或外國監管機構頒發的所有證書、授權和許可，但如無法合理預期該等證書、授權或許可不會導致重大不利影響(“實質性許可”)，並且本公司或任何子公司均未收到任何與撤銷或修改任何實質性許可有關的訴訟通知，則屬例外。(O)資產所有權。本公司及附屬公司對其擁有的所有不動產及對本公司及附屬公司的業務有重大影響的所有非土地財產均擁有良好及可出售的費用所有權，但不包括所有留置權，但(I)不會對該等財產的價值造成重大影響及不會對本公司及附屬公司擬使用該等財產造成或擬作出重大幹擾的留置權除外，及(Ii)已根據公認會計原則為支付聯邦、州或其他税項預留適當的留置權。它的支付既不拖欠，也不受懲罰。本公司及附屬公司根據租約持有的任何不動產及設施，均根據本公司及附屬公司遵守的有效、存續及可強制執行的租約持有。(P)知識產權。公司及其附屬公司擁有或有權使用美國證券交易委員會報告中所述與各自業務相關的所有專利、專利申請、商標、商標申請、服務商標、商號、商業祕密、發明、版權、許可和其他知識產權以及類似的權利，如果不具備該等權利，將有理由認為不具備該等權利將產生重大不利影響(統稱為“知識產權”)。自本協議之日起兩(2)年內，本公司或任何附屬公司均未收到任何知識產權已到期、終止或放棄、或預期將到期、終止或放棄的通知(書面或其他)，除非該到期、終止或放棄不會單獨或整體產生重大不利影響。自美國證券交易委員會報告中包含的最新經審計財務報表之日起，本公司或任何子公司均未收到關於知識產權侵犯或侵犯任何人權利的書面索賠通知或其他通知，除非不可能或合理地預期不會產生實質性的不利影響。據本公司所知，所有此等知識產權均可強制執行，目前並無任何其他人侵犯任何知識產權。本公司及其附屬公司已採取合理的保安措施，以保護其所有知識產權的保密性、保密性及價值，但如未能採取措施，可能不會個別或整體產生重大不利影響，則屬例外。

12(Q)保險。本公司及其附屬公司由具有公認財務責任的保險人為該等損失及風險提供保險，承保金額為本公司及其附屬公司所從事業務的審慎及慣常金額，包括但不限於董事及高級管理人員的保險範圍至少等於總認購金額。本公司或任何附屬公司均無理由相信其將無法在現有保險範圍屆滿時續期，或無法在不大幅增加成本的情況下，從類似的保險公司取得類似的保障，以繼續其業務。(R)與關聯公司和僱員的交易。除附表3.1(R)所列者外，本公司或任何附屬公司的高級職員或董事，以及據本公司所知，本公司或任何附屬公司的僱員目前並無參與與本公司或任何附屬公司的任何交易(作為僱員、高級職員及董事的服務除外)，包括任何合約、協議或其他安排，規定向或由董事或該等僱員提供服務，規定向或從任何高級職員借入或借出款項，或規定向或以其他方式要求向任何高級職員、董事或上述僱員或據本公司所知，任何高級職員、董事或任何有關僱員擁有重大權益或身為高級職員、董事、受託人、股東、成員或合夥人的任何實體，於每個情況下均須支付超過120,000美元，但(I)支付所提供服務的薪金或顧問費，(Ii)報銷代表本公司或其附屬公司產生的開支，及(Iii)支付其他僱員福利，包括根據本公司任何股票期權計劃訂立的認股權協議，則除外。(S)《薩班斯-奧克斯利法案》；內部會計控制。公司及其子公司遵守經修訂的2002年《薩班斯-奧克斯利法案》的任何和所有適用的要求，以及委員會根據該法案頒佈的、自本文件之日和截止日期起生效的任何和所有適用的規則和條例。本公司及其附屬公司維持一套足以提供合理保證的內部會計控制制度，以確保：(I)交易是根據管理層的一般或特別授權進行，(Ii)交易按需要記錄，以便根據適用的證券法及公認會計原則編制財務報表，並維持資產責任，(Iii)只有根據管理層的一般或特定授權，方可接觸資產，及(Iv)已記錄的資產責任按合理間隔與現有資產進行比較，並就任何差異採取適當行動。本公司及其附屬公司已為本公司及附屬公司設立披露控制及程序(定義見交易所法案規則13a-15(E)及15d-15(E))，並設計該等披露控制及程序，以確保本公司須在根據交易法提交或提交的報告中披露的資料，在委員會的規則及表格所指定的期限內予以記錄、處理、總結及報告。本公司的核證員已評估本公司及其附屬公司的披露控制及程序於最近根據交易所法案提交的定期報告所涵蓋的期間(該日期，即“評估日期”)結束時的有效性。本公司在其根據《交易所法案》提交的最新定期報告中，根據截至評估日期的評估，提交了認證人員對披露控制和程序的有效性的結論。自評估日期起，本公司及其附屬公司的財務報告內部控制(定義見交易法)並無重大影響或合理地可能會對本公司及其附屬公司的財務報告內部控制產生重大影響的變動。(T)某些費用。除本公司應付予配售代理的費用外，本公司或任何附屬公司不會或將不會就交易文件擬進行的交易向任何經紀、財務顧問或顧問、找尋人、配售代理、投資銀行、銀行或其他人士支付經紀、財務顧問或顧問、找尋人、配售代理、投資銀行、銀行或其他人士的經紀或找尋佣金。買方不應對任何費用或其他人或其代表提出的任何索賠承擔任何義務，要求支付與交易文件預期的交易相關的本節所述類型的費用。(U)投資公司。本公司不是，也不是聯營公司，在收到證券付款後，將不會是1940年修訂的《投資公司法》所指的“投資公司”，也不會是聯營公司。本公司的經營方式應使其不會成為一家“投資公司”，但須根據修訂後的1940年《投資公司法》進行登記。

13(V)登記權。除附表3.1(V)所載者外，任何人士均無權促使本公司根據證券法對本公司或任何附屬公司的任何證券進行登記。(W)上市和維護要求。普通股是根據《證券交易法》第12(B)或12(G)條登記的，本公司並未採取任何旨在或據其所知可能會根據《證券交易法》終止普通股登記的行動，本公司也未收到任何委員會正在考慮終止此類登記的通知。除美國證券交易委員會報告所披露者外，本公司於本報告日期前12個月內並無接獲任何普通股上市或報價市場發出有關本公司不符合該等交易市場上市或維持規定的通知。普通股股份目前有資格透過存託信託公司或另一間已成立結算公司以電子方式轉讓，而本公司正向存託信託公司(或該等其他已成立結算公司)支付有關電子轉讓的費用。(X)接管保護的適用。本公司及董事會已採取一切必要行動(如有)，以使本公司的公司註冊證書(或類似的章程文件)或其公司註冊國家的法律中因買方及本公司履行其義務或行使其在交易文件下的權利而適用於買方的任何控制權股份收購、業務合併、毒丸(包括根據權利協議作出的任何分派)或其他類似的反收購條文不再適用，包括但不限於本公司發行證券及買方對證券的所有權所致。(Y)披露。除交易文件擬進行的交易的重大條款及條件外，本公司確認，本公司或任何代表本公司行事的人士均未向任何買方或其代理人或大律師提供其認為構成或可能構成重大非公開資料的任何資料，而該等資料並未在美國證券交易委員會報告中以其他方式披露。本公司理解並確認，買方在進行本公司證券交易時將依賴前述陳述。本公司或代表本公司向買方提供的有關本公司及其附屬公司、其各自業務及擬進行的交易的所有披露(包括本協議的披露附表)在所有重大方面均屬真實及正確，且不包含對重大事實的任何不真實陳述或遺漏陳述任何必要的重大事實，以根據作出陳述的情況作出不具誤導性的陳述。本公司在本協議日期前12個月內發佈的新聞稿作為一個整體，不包含對重大事實的任何不真實陳述，或遺漏陳述其中所要求陳述的或為作出陳述所必需的重大事實，考慮到這些陳述是在何種情況下作出的，並且在作出時不具有誤導性。本公司承認並同意，除本協議第3.2節明確規定的交易外，買方不會就本協議擬進行的交易作出或作出任何其他陳述或保證。(Z)無集成產品。假設第3.2節所載買方陳述及保證的準確性，本公司或其任何聯屬公司，或代表本公司或其代表行事的任何人士，並無直接或間接提出任何證券的要約或出售，或徵求任何證券的要約以購買任何證券，而該等情況會導致本公司就本公司任何證券上市或指定的任何交易市場的任何適用股東批准條款而言，將本次證券發售與本公司先前的發售合併。(Aa)償付能力。根據本公司於截止日期的綜合財務狀況，於本公司收到出售證券所得款項生效後，(I)本公司資產的公平可出售價值超過本公司現有債務及其他負債(包括已知或有負債)到期時將須支付的金額，(Ii)本公司的資產並不構成不合理的小額資本，以經營其現時及擬進行的業務，包括考慮到本公司所進行業務的特別資本需求，(I)綜合及預計資本需求及其資本供應；及(Iii)本公司目前的現金流，連同本公司將收到的收益，於考慮現金的所有預期用途後，如將其全部資產變現，將足以在需要支付該等款項時支付其負債的所有款項。本公司不打算產生超出其到期償付能力的債務(考慮到現金的時間和金額

14須就其債項或就其債項而支付)。本公司並不知悉任何事實或情況令其相信本公司將於結算日起計一年內根據任何司法管轄區的破產法或重組法申請重組或清盤。附表3.1(Aa)列明截至本協議日期，本公司或任何附屬公司的所有未償還擔保及無擔保債務，或本公司或任何附屬公司承擔的所有債務。就本協議而言，“負債”係指(X)借款或所欠金額超過50,000美元的任何負債(正常業務過程中發生的應付貿易賬款除外)，(Y)與他人負債有關的所有擔保、背書和其他或有債務，無論其是否反映在或應反映在公司的綜合資產負債表(或其附註)中，但在正常業務過程中通過背書用於存款或託收或類似交易的可轉讓票據的擔保除外；及(Z)根據根據公認會計準則須資本化的租約所應付的超過50,000美元的任何租賃付款的現值。本公司或任何附屬公司均不存在任何債務違約。(Bb)遵守税務規定。除個別或整體不會或合理地預期不會導致重大不利影響的事項外，本公司及其附屬公司各自(I)已作出或提交其所屬司法管轄區所要求的所有聯邦、州及地方收入及所有外國納税申報單、報告及聲明，(Ii)已繳付所有税款及其他政府評税及收費，而該等申報單、報告及聲明所顯示或確定為應付的款額屬重大，及(Iii)已在其賬面上預留合理足夠的撥備，以支付該等報税表、報告及聲明所涉期間之後的所有重大税項，適用報告或聲明。任何司法管轄區的税務機關並無聲稱應繳任何重大金額的未繳税款，而本公司或任何附屬公司的高級人員亦不知道任何該等申索的依據。(Cc)外國腐敗行為。本公司或任何附屬公司，或據本公司或任何附屬公司所知，代表本公司或任何附屬公司行事的任何代理人或其他人士，均未(I)直接或間接地將任何資金用於與外國或國內政治活動有關的非法捐款、禮物、娛樂或其他非法開支，(Ii)從公司資金中非法向外國或國內政府官員或僱員或向任何外國或國內政黨或競選活動支付任何款項，(Iii)未能全面披露本公司或任何附屬公司(或本公司知悉代表本公司行事的任何人士)作出的任何違反法律的貢獻，或(Iv)在任何重大方面違反《反海外腐敗法》的任何規定。(Dd)會計師。該公司的獨立註冊會計師事務所是Haskell&White LLP。據本公司所知及所信，該會計師事務所(I)為交易所法令所規定的註冊會計師事務所，(Ii)應就將納入本公司截至2023年12月31日的財政年度報告內的財務報表發表意見。(Ee)對買方購買證券的確認。本公司確認並同意，據本公司所知，就交易文件及擬進行的交易而言，各買方僅以獨立買方的身份行事。本公司進一步確認，據本公司所知，就交易文件及擬進行的交易而言，並無買方擔任本公司的財務顧問或受信人(或以任何類似身分)，而任何買方或彼等各自的代表或代理人就交易文件及擬進行的交易提供的任何意見僅屬買方購買證券的附帶事宜。本公司進一步向各買方表示，本公司訂立本協議及其他交易文件的決定，完全基於本公司及其代表對擬進行的交易所作的獨立評估。(Ff)確認買方的交易活動。儘管本協議或本協議其他部分有任何相反規定(本協議第4.11條除外)，但本公司理解並確認：(I)本公司沒有要求任何買方同意，也沒有任何買方同意停止購買或出售本公司的長期和/或短期證券，或基於本公司發行的證券的“衍生”證券，或在任何特定期限內持有該證券；(Ii)任何買方過去或未來進行的公開市場交易或其他交易，特別包括但不限於在本次或未來私募交易結束之前或之後進行的賣空或“衍生”交易，可能會對本公司公開交易證券的市場價格產生負面影響；。(Iii)任何買方及“衍生”交易的交易對手。

15任何該等買方直接或間接參與的交易，目前可能在普通股中持有“淡倉”，及(Iv)每名買方不得被視為與任何“衍生”交易中的任何公平交易對手有任何聯繫或控制。本公司進一步理解並承認(Y)一名或多名買方可能於證券未清償期間的不同時間進行對衝活動，及(Z)該等對衝活動(如有)可能會在進行對衝活動時及之後減少現有股東於本公司的權益的價值。本公司承認，上述對衝活動並不構成違反任何交易文件。(Gg)遵守M規則。本公司並無，據其所知，並無(I)直接或間接採取任何行動，以導致或導致穩定或操縱本公司任何證券的價格，以便利出售或轉售任何該等證券；(Ii)出售、競投、購買或支付任何該等證券的任何補償，或(Iii)因招攬他人購買本公司任何其他證券而向任何人支付或同意支付任何補償，第(Ii)及(Iii)條的情況除外，向配售代理支付的與證券配售相關的補償。(Hh)FDA。對於由公司或其任何子公司製造、包裝、貼標籤、測試、分銷、銷售和/或營銷的受美國食品和藥物管理局(FDA)管轄的經修訂的《聯邦食品、藥物和化粧品法》及其下的法規(FDCA)下的每一種產品(每個該等產品，即“醫藥產品”)，該醫藥產品由公司製造、包裝、標籤、測試、分銷、銷售和/或營銷，符合FDCA和類似法律、規則和法規下有關注冊、研究使用、上市前批准、許可或申請批准、良好的製造規範、良好的實驗室規範、良好的臨牀規範、產品上市、配額、標籤、廣告、記錄保存和報告的歸檔，除非不符合規定不會有實質性的不利影響。不存在針對公司或其任何子公司的未決的、已完成的或據公司所知的針對公司或其任何子公司的任何威脅、行動(包括任何訴訟、仲裁或法律、行政或監管程序、指控、投訴或調查)，公司或其任何子公司也未收到來自FDA或任何其他政府實體的任何通知、警告信或其他通信，這些通知、警告信或其他通信包括：(I)對任何醫藥產品的使用、分銷、製造或包裝、測試、銷售或標籤和宣傳提出異議；(Ii)撤回對任何醫藥產品的批准，要求召回、暫停或扣押，或撤回或命令撤回與任何醫藥產品有關的廣告或促銷資料，(Iii)對公司或其任何附屬公司的任何臨牀調查施加臨牀擱置，(Iv)禁止在公司或其任何附屬公司的任何設施生產，(V)與公司或其任何附屬公司訂立或建議訂立永久禁令的同意法令，或(Vi)以其他方式指稱公司或其任何附屬公司違反任何法律、規則或法規，無論是單獨的還是總體的，都會產生實質性的不利影響。本公司的物業、業務和運營一直並正在按照FDA的所有適用法律、規則和法規在所有實質性方面進行。FDA尚未通知本公司，FDA將禁止在美國銷售、銷售、許可或使用本公司擬開發、生產或營銷的任何產品，FDA也未對批准或批准本公司正在開發或擬開發的任何產品上市表示任何擔憂。(Ii)股票期權計劃。本公司根據本公司的股票期權計劃授予的每一項股票期權，(I)根據該計劃的條款授予，(Ii)行使價格至少等於根據公認會計原則和適用法律考慮授予該股票期權當日普通股的公平市場價值。根據公司的股票期權計劃授予的股票期權沒有回溯日期。本公司在發佈或以其他方式公開公佈有關本公司或其附屬公司或其財務業績或前景的重大資料之前，並沒有、亦沒有、亦沒有任何公司政策或做法，在知情情況下授予股票期權，或以其他方式在知情情況下協調授予股票期權。(JJ)網絡安全(I)本公司或其附屬公司的任何資訊科技及電腦系統、網絡、硬件、軟件、數據(包括其各自客户、僱員、供應商、供應商及由其或其代表維護的任何第三方數據)、設備或技術(統稱為“資訊科技系統及數據”)並無重大安全漏洞或其他危害，或與該等資訊科技系統及數據有關的任何重大安全漏洞或其他危害；。(Ii)本公司及其附屬公司並未接獲有關其資訊科技系統及數據的任何重大保安漏洞或其他危害的通知，亦不知悉任何可合理預期會導致任何重大安全漏洞或其他危害的事件或情況。(Iii)

16公司及其子公司目前在所有重要方面都遵守所有適用的法律或法規，以及任何法院或仲裁員或政府或監管機構的所有判決、命令、規則和條例，內部政策和與IT系統和數據的隱私和安全以及保護此類IT系統和數據免受未經授權的使用、訪問、挪用或修改有關的合同義務，但不會單獨或整體產生重大不利影響的除外；(Iv)本公司及其附屬公司已實施及維持商業上合理的保障措施，以維持及保護其重要機密資料及所有資訊科技系統及數據的完整性、持續運作、宂餘及安全；及(V)本公司及其附屬公司已實施符合行業標準及慣例的備份及災難恢復技術。(KK)外國資產管制辦公室。據本公司所知，本公司或其任何附屬公司，或據本公司所知，本公司或其任何附屬公司的任何董事、高級管理人員、代理人、僱員或附屬公司目前均不受美國財政部外國資產控制辦公室(“OFAC”)實施的任何美國製裁。(Ll)美國不動產控股公司。本公司不是，也從來不是1986年修訂的《國税法》第897條所指的美國房地產控股公司，應買方要求，本公司應予以證明。(Mm)《銀行控股公司法》。本公司及其任何附屬公司或聯營公司均不受經修訂的1956年銀行控股公司法(“BHCA”)及美國聯邦儲備系統理事會(“美聯儲”)的監管。本公司及其任何附屬公司或聯屬公司均不直接或間接擁有或控制任何類別有投票權證券的5%(5%)或以上的流通股，或銀行或受BHCA及美聯儲監管的任何實體總股本的25%(25%)或以上。本公司或其任何附屬公司或聯屬公司均不會對受BHCA和美聯儲監管的銀行或任何實體的管理或政策施加控制性影響。(NN)洗錢。本公司及其子公司的業務在任何時候都符合經修訂的1970年《貨幣和外國交易報告法》適用的財務記錄保存和報告要求、適用的洗錢法規及其下的適用規則和條例(統稱為《洗錢法》)，涉及本公司或任何子公司的任何法院、政府機構、當局或機構或任何仲裁員在洗錢法律方面的任何訴訟或訴訟均未進行，據本公司或任何子公司所知，沒有任何訴訟或訴訟受到威脅。(OO)私募。假設第3.2節規定的買方陳述和擔保的準確性，本公司向買方出售證券不需要根據證券法進行登記。(PP)不得進行一般徵求意見。本公司或代表本公司行事的任何人士均未以任何形式的一般招股或一般廣告形式發售或出售任何證券。根據證券法第501條的規定，公司僅將證券出售給作為“認可投資者”的每一位買方。(QQ)沒有取消資格的事件。關於將根據證券法第506條發行和出售的證券，本公司、其任何前身、任何關聯發行人、任何董事、高管、參與本協議項下發售的本公司其他高管、持有本公司20%或以上已發行有表決權股權證券的任何實益擁有人、也沒有任何發起人(該術語在證券法第405條中定義)在出售時以任何身份與本公司相關(各自，發行人受《證券法》第506(D)(1)(I)至(Viii)條所述的任何“不良行為人”取消資格(“取消資格事件”)，但規則第506(D)(2)或(D)(3)條所述的取消資格事件除外。本公司已採取合理的謹慎措施，以確定是否有任何發行人承保人員受到取消資格事件的影響。本公司已在適用範圍內遵守規則506(E)項下的披露義務，並已向每名買方提供一份根據該規則提供的任何披露的副本。

17(Rr)其他承保人。除配售代理外，本公司並不知悉任何人士(發行人涵蓋人士除外)已獲支付或將獲支付(直接或間接)與出售任何證券有關的招攬買主的酬金。(Ss)取消資格的通知。本公司將於下列事項結束日期前以書面通知買方：(I)任何與發行人承保人士有關的取消資格事件及(Ii)任何可合理預期會隨着時間推移成為與發行人承保人士有關的取消資格事件，而該等事件均為本公司所知悉的。3.2買方的陳述和保證。每一位買方在此向本公司作出如下聲明和保證：(A)組織；當局；(A)組織；(B)在本協議生效之日和截止日期向本公司作出以下保證(除非是在本協議的特定日期，在這種情況下，該日期應準確)。該買方為個人或正式註冊成立或組成的實體，根據其註冊成立或成立的司法管轄區的法律有效存在及信譽良好，並有權訂立及完成交易文件所擬進行的交易及以其他方式履行其於本協議及本協議項下的義務。買方簽署及交付交易文件及履行交易文件所擬進行的交易，已獲該買方採取一切必要的公司、合夥、有限責任公司或類似行動(視何者適用而定)而妥為授權。買方正式簽署的每一份交易文件，當買方按照本協議的條款交付時，將構成買方的有效和具有法律約束力的義務，並可根據其條款對其強制執行，但以下情況除外：(I)受一般衡平原則和適用的破產、破產、重組、暫停和其他一般適用法律的限制，這些法律一般影響債權人權利的執行；(Ii)受有關特定履約、強制救濟或其他衡平法救濟的法律的限制；及(Iii)賠償和分擔條款可能受到適用法律的限制。(B)諒解或安排。該等買方(I)明白該證券並未根據證券法或任何適用的州證券法註冊；(Ii)為其本身以本金的身份收購該證券；及(Iii)與任何其他人士並無直接或間接的安排或諒解以分銷或分銷該等證券(本聲明及保證並不限制該買方根據有效的註冊聲明或符合適用的聯邦及州證券法的其他規定出售該證券的權利)。該買方是作為他/她或她自己賬户的本金收購證券的，目的不是為了或為了分發或再銷售該證券或其任何部分，違反證券法或任何適用的州證券法，目前無意在違反證券法或任何適用的州證券法的情況下分發任何該等證券，並且與任何其他人沒有違反證券法或任何適用的州證券法來分發或關於分發該等證券的直接或間接安排或諒解。該買方在其正常業務過程中收購本協議項下的證券。(C)一般徵求意見。該買方並非因在任何報章、雜誌或類似媒體上刊登或透過電視或電臺廣播或在任何研討會上介紹或據該買方所知的任何其他一般招攬或一般廣告而購買該證券。(D)買方身份。在向該買方提供該證券時，該買方是，截至本協議日期，在其行使任何認股權證的每個日期，該買方將是：(I)規則501(A)(1)、(A)(2)、(A)(3)、(A)(7)、(A)(8)、(A)(9)、(A)(12)所界定的“認可投資者”，或(A)(13)證券法下的“合格機構買家”或(Ii)證券法下第144A(A)條所界定的“合格機構買家”。(E)該買方的經驗。該買方(不論單獨或連同其代表)在商業及金融事務方面具備所需知識、經驗及經驗，足以評估該證券的預期投資的優點及風險，並已就該等投資的優點及風險作出評估。該買方有能力承擔證券投資的經濟風險，且目前有能力承擔該項投資的全部損失。

18(F)獲取信息。買方承認，其已有機會審閲交易文件(包括所有證物和時間表)以及美國證券交易委員會報告，並已獲得：(I)有機會就發售證券的條款和條件以及投資於證券的優點和風險向公司代表提出其認為必要的問題，並獲得他們的答覆；(Ii)獲得有關公司及其財務狀況、運營結果、業務、物業、管理和前景的信息，以使其能夠評估其投資；及(Iii)有機會取得本公司所擁有或可在沒有不合理努力或開支的情況下取得的額外資料，而該等額外資料是就該項投資作出知情投資決定所必需的。該買方確認並同意，該配售代理或該配售代理的任何聯營公司均未向該買方提供有關該證券的任何資料或建議，亦無需要或期望該等資料或建議。配售代理或任何聯營公司均未就本公司或證券及配售代理的質素作出任何陳述或作出任何陳述，而任何聯營公司可能已獲取有關本公司的非公開資料，而該買方同意無須向其提供該等資料。就向該買方發行證券而言，配售代理或其任何聯營公司並無擔任該買方的財務顧問或受信人。(G)某些交易和保密。除完成本協議項下擬進行的交易外，自買方首次從本公司或代表本公司的任何其他人士收到本公司或代表本公司的任何其他人士發出列明本協議項下擬進行的交易的主要條款(包括最終定價條款)起計的期間內，該買方並無直接或間接買入或出售本公司證券，包括賣空，該等條款包括最終定價條款。儘管如上所述，如果買方是一個多管理的投資工具，其中獨立的投資組合經理管理着買方資產的單獨部分，而投資組合經理並不直接瞭解管理買方資產其他部分的投資組合經理所做出的投資決定，則上述陳述僅適用於做出投資決定購買本協議所涵蓋證券的投資組合經理管理的資產部分。除本協議另一方或買方代表以外，包括但不限於其高級管理人員、董事、合夥人、法律和其他顧問、僱員、代理人和關聯公司，買方對向其披露的與本次交易有關的所有信息(包括本次交易的存在和條款)保密。儘管如上所述，為免生疑問，本文所載任何內容均不構成關於尋找或借入股份以在未來進行賣空或類似交易的陳述或擔保，或排除任何行動。(H)獨立諮詢。各買方明白，本協議或本公司或其代表向買方提交的與購買證券有關的任何其他材料，均不構成法律、税務或投資建議。本公司承認並同意，本第3.2節中包含的陳述不得修改、修改或影響買方依賴本協議中包含的本公司陳述和保證，或任何其他交易文件中包含的任何陳述和保證，或與本協議或本協議預期交易的完成相關而簽署和/或交付的任何其他文件或文書中包含的任何陳述和保證。儘管如上所述，為免生疑問，本文所載任何內容均不構成關於尋找或借入股份以在未來進行賣空或類似交易的陳述或擔保，或排除任何行動。4.1轉讓限制(A)證券只能在符合州和聯邦證券法的情況下出售。本公司可要求轉讓人向本公司或買方的關聯公司或與4.1(B)節所述的質押有關的任何證券轉讓，而不是根據有效的登記聲明或第144條規則，要求轉讓人向本公司提供轉讓人選擇的、本公司合理接受的大律師的意見，意見的形式和實質應合理令人滿意

19向本公司轉讓，大意是這種轉讓不需要根據證券法登記此類轉讓的證券。作為轉讓的條件，任何此類受讓人應以書面形式同意受本協議條款的約束，並享有本協議項下買方的權利和義務。(B)買方同意在本第4.1節要求的情況下，以下列形式在任何證券上印製圖例：[都不是] THIS SECURITY [NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE][HAS NOT/HAVE] BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES. The Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an “accredited investor” as defined in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, such Purchaser may transfer pledged or secured Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate Purchaser’s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities, including, if the Securities are subject to registration pursuant to Section 4.15 of this Agreement, the preparation and filing of any required prospectus supplement under Rule 424(b)(3) under the Securities Act or other applicable provision of the Securities Act to appropriately amend the list of selling shareholders thereunder. The Company agrees to cause such legend to be removed immediately upon effectiveness of a Registration Statement (“Effectiveness Date”) and Warrant Shares being issued after the Effectiveness Date shall be free of all legends. (c) Certificates evidencing the Securities shall not contain any legend (including the legend set forth in Section 4.1(b) hereof): (i) while a registration statement covering the resale of such security is effective under the Securities Act, or (ii) following any sale of such Warrant Shares pursuant to Rule 144 (assuming cashless exercise of the Warrants), or (iii) if such Warrant Shares are eligible for sale under Rule 144 (assuming cashless exercise of the Warrants) without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such Securities and without volume or manner-of-sale restrictions, or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent or the Purchaser promptly if required by the Transfer Agent to effect the removal of the legend hereunder, or if requested by a Purchaser, respectively. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the resale of the Warrant Shares, or if such Warrant Shares may be sold under Rule 144 and the Company is then in compliance with the current public information required under Rule 144 (assuming cashless exercise of the Warrants), or if the Warrant Shares may be sold under Rule 144 without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such Warrant Shares, or if such legend is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission) then such Warrant Shares shall be issued free of all legends. The Company agrees that following such time as such legend is no longer

20 required under this Section 4.1(c), the Company will, no later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing Warrant Shares, as applicable, issued with a restrictive legend (such date, the “Legend Removal Date”), deliver or cause to be delivered to such Purchaser a book entry statement representing such shares that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4. Warrant Shares subject to legend removal hereunder shall be transmitted by the Transfer Agent to the Purchaser by crediting the account of the Purchaser’s prime broker with the Depository Trust Company System as directed by such Purchaser. As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of a certificate representing Warrant Shares issued with a restrictive legend. (d) In addition to such Purchaser’s other available remedies, the Company shall pay to a Purchaser, in cash, either (i) as partial liquidated damages and not as a penalty, for each $1,000 of Warrant Shares (based on the VWAP of the Common Stock on the date such Securities are submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section 4.1(c), $10 per Trading Day (increasing to $20 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to a Purchaser by the Legend Removal Date a certificate representing the Securities so delivered to the Company by such Purchaser that is free from all restrictive and other legends or (b) if after the Legend Removal Date such Purchaser purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Purchaser of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock, that such Purchaser anticipated receiving from the Company without any restrictive legend, then an amount equal to the excess of such Purchaser’s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the “Buy-In Price”) over the product of (A) such number of Warrant Shares that the Company was required to deliver to such Purchaser by the Legend Removal Date multiplied by (B) the lowest closing sale price of the Common Stock on any Trading Day during the period commencing on the date of the delivery by such Purchaser to the Company of the applicable Warrant Shares (as the case may be) and ending on the date of such delivery and payment under this Section 4.1(d). (e) Each Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will sell any Securities pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if Securities are sold pursuant to a Registration Statement, they will be sold in compliance with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates representing Securities as set forth in this Section 4.1 is predicated upon the Company’s reliance upon this understanding. 4.2 Furnishing of Information; Public Information. Until the earlier of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired or been exercised in full, the Company covenants to maintain the registration of the Common Stock under Section 12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act, even if the Company is not then subject to the reporting requirements of the Exchange Act, except in the event that the Company consummates (in each case on or after the date as of which the Purchasers may sell all of their Securities without restriction or limitation pursuant to Rule 144): (a) any transaction or series of related transactions as a result of which any Person (together with its Affiliates) acquires then outstanding securities of the Company representing more than fifty percent (50%) of the voting control of the Company; (b) a merger or reorganization of the Company with one or more other entities in which the Company is not the surviving entity; or (c) a sale of all or substantially all of the assets of the Company, where the consummation of such transaction results in the Company no longer being subject to the reporting requirements of the Exchange Act. 4.3 Integration. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder

21 approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction. 4.4 Securities Laws Disclosure; Publicity. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate and be no further force or effect. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure. 4.5 Shareholder Rights Plan. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an “Acquiring Person” under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers. 4.6 Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public information to a Purchaser without such Purchaser’s consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.

22 4.7 Use of Proceeds. The Company shall not use the proceeds from the sale of the Securities: (a) for the satisfaction of any portion of the Company’s debt (other than payment of trade payables in the ordinary course of the Company’s business or repayment of obligations outstanding as of the date of this Agreement consistent with prior practices), (b) for the redemption of any shares of Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations or similar applicable regulations. 4.8 Indemnification of Purchasers. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a “Purchaser Party”) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any shareholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such Purchaser Party’s representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such shareholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct. If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and, the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement for any settlement by a Purchaser Party effected without the Company’s prior written consent, which shall not be unreasonably withheld or delayed, or to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party’s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred; provided that, if any Purchaser Party is finally judicially determined not to be entitled to indemnification or payment under this Section 4.8, such Purchaser Party shall promptly reimburse the Company for any payments that are advanced pursuant to this provision. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law. 4.9 Listing of Shares. The Company hereby agrees to use commercially reasonable efforts to maintain the listing or quotation of the Common Stock on each Trading Market on which each is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Shares and the Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and the Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application all of the Shares and the Warrant Shares, and will take such other action as is necessary to cause all of the Shares and the Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of the Common Stock on a Trading Market and will comply in all material respects with the Company’s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to use commercially reasonable efforts to maintain the eligibility of the for electronic transfer through the Depository Trust

23 Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer. 4.10 Equal Treatment of Purchasers. No consideration (including any modification of the Transaction Documents) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of the Securities or otherwise. 4.11 Certain Transactions and Confidentiality. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales of any of the Company’s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the Disclosure Schedules (other than as disclosed to its legal and other representatives). Notwithstanding the foregoing, and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agent, including, without limitation, the Placement Agent, after the issuance of the initial press release as described in Section 4.4. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. 4.12 Reservations of Shares. As of the date of filing the Amendment to Certificate of Incorporation, the Company will have reserved and shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue shares of Common Stock pursuant to this Agreement. 4.13 Form D; Blue Sky Filings. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers at the Closing under applicable securities or “Blue Sky” laws of the states of the United States, and shall provide evidence of such actions promptly upon request of any Purchaser. 4.14 Subsequent Sales of Securities (a) From the date hereof until the later to occur of (A) the six (6) month anniversary of the effective date of the Registration Statement and (B) thirty (30) calendar days following the Shareholder Approval Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents, (ii) file any registration statement or amendment or supplement thereto relating to the offering or resale of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company (other than

24 the Registration Statement or a registration statement on Form S-8 in connection with any employee benefit plan), or (iii) enter into any swap or other arrangement that transfers to another Person, in whole or in part, any of the economic consequences of ownership of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company. (b) From the date hereof until the six (6) month anniversary of the Closing Date, neither the Company nor any Subsidiary shall effect or enter into an agreement to effect any issuance by the Company or any of its Subsidiaries of shares of Common Stock or Common Stock Equivalents (or a combination thereof) involving a Variable Rate Transaction. “Variable Rate Transaction” means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the Common Stock at any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for shares of Common Stock, or (ii) enters into, or effects a transaction under, any agreement whereby the Company may issue securities at a future determined price. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages. (c) Notwithstanding the foregoing, this Section 4.14 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an Exempt Issuance. 4.15 Registration Statement (a) As soon as practicable (and in any event within 30 calendar days of the date of this Agreement), the Company shall file a registration statement on Form S-3, or if Form S-3 is not available, Form S-1 or any successor forms thereto (the “Registration Statement”), providing for the resale by the Purchasers of the Shares and the Warrant Shares (the “Registrable Securities”). The Company shall use its best efforts to cause the Registration Statement to become effective within 60 days (90 days in the event the Commission elects to review the Registration Statement) following the Closing Date and to keep such Registration Statement effective at all times until no Purchaser owns any Securities (the “Effectiveness Period”). In the event that the Commission notifies the Company that it has elected not to review the Registration Statement, the Company shall, subject to applicable law, request acceleration of the Registration Statement for an effective date that is no later than three (3) Business Days following the date when the Company receives such notification from the Commission. (b) If (i) any Registration Statement is not filed within the time frame set forth in this Section 4.15, (ii) any Registration Statement is not declared effective within the time frame set forth in this Section 4.15, or (iii) on any day during the Effectiveness Period and after the date on which the Registration Statement is declared effective, sales of all of the Registrable Securities required to be included on the Registration Statement cannot be made pursuant to the Registration Statement (including because of a failure to keep such Registration Statement effective, to disclose such information as is necessary for sales to be made pursuant to the Registration Statement or to register a sufficient number of shares of Common Stock as required by this Agreement) (any such failure being referred to as an “Event”), then, in satisfaction of the damages to the Purchaser by reason of any such delay in or reduction of its ability to sell the Registrable Securities, the Company shall pay to each Purchaser of Registrable Securities relating to such Registration Statement an amount in cash equal to 1.0% multiplied by the aggregate purchase price paid by the Purchaser for the Registrable Securities then held by such Purchaser on every thirtieth (30th) day (prorated for periods totaling less than 30 days) following the date on which such Event occurs until such Event is cured. The maximum aggregate liquidated damages payable to a Purchaser pursuant to this Section 4.15 shall be 6.0% of the Subscription Amount paid by such Purchaser pursuant to this Agreement. The liquidated damages pursuant to the terms hereof shall apply on a daily pro rata basis for any portion of a month prior to the cure of an Event. Notwithstanding the foregoing, the Company shall not owe any liquidated damages to any Purchaser pursuant to this Section 4.15 if, at the time of the Event, such Purchaser may sell the Shares held by such Purchaser pursuant to Rule 144 without volume restrictions or current public information requirements. 4.16 Shareholder Approval. The Company covenants that it shall use its best efforts to hold a special or annual meeting of shareholders no later than May 3, 2024, with the recommendation of the Board of Directors that

25 proposals (i) approving an increase in the number of authorized shares of Common Stock sufficient for the issuance of the Common Warrants and the Common Warrant Shares upon the exercise thereof and (ii) allowing for the issuance of the Common Warrant Shares in accordance with the rules and regulations of the Nasdaq Stock Market, and the Company shall solicit proxies from its shareholders in connection therewith in the same manner as all other management proposals in such proxy statement and all management-appointed proxyholders shall vote their proxies in favor of such proposal. If the Company does not obtain shareholder approval of such proposals (“Shareholder Approvals”) at the first meeting, the Company shall use its best efforts to call a meeting every 90 days thereafter to seek Shareholder Approvals until the earlier of the date Shareholder Approvals are obtained or the Common Warrants are no longer outstanding. SECTION 5. MISCELLANEOUS 5.1 Termination. This Agreement may be terminated by any Purchaser, as to such Purchaser’s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated on or before the fifth (5th) Trading Day following the date hereof; provided, however, that no such termination will affect the right of any party to sue for any breach by any other party (or parties). 5.2 Fees and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent Fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers. 5.3 Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules. 5.4 Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto. 5.5 Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers which purchased at least 50.1% in interest of the Shares, or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought; provided, that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.

26 5.6 Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. 5.7 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than to the surviving corporation with or into which the Company or permitted assignee may merge or consolidate or an entity to which the Company or assignee transfers all, or substantially all, of its business and assets). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to the “Purchasers.” 5.8 No Third-Party Beneficiaries. The Placement Agent shall be the third-party beneficiary of the representations and warranties of the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8. 5.9 Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an Action, suit or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section 4.8, the prevailing party in such Action, suit or Proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding. 5.10 Survival. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities. 5.11 Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such “.pdf” signature page were an original thereof. 5.12 Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the

27 remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable. 5.13 Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document, and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights; provided, however, that, in the case of a rescission of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration of such Purchaser’s right to acquire such shares pursuant to such Warrant (including, issuance of a replacement warrant certificate evidencing such restored right). 5.14 Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities. 5.15 Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would be adequate. 5.16 Payment Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred. 5.17 Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through the Placement Agent Counsel, the legal counsel of the Placement Agent. Placement Agent Counsel does not represent any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.

28 5.18 Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day. 5.19 Liquidated Damages. The Company’s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due and payable shall have been canceled. 5.20 Construction. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions relating to shares of Common Stock that occur after the date of this Agreement. 5.21 WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. [Signature Pages Follow]

29 IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. KIORA PHARMACEUTICALS, INC. Address for Notice: 332 Encinitas Boulevard By: /s/ Brian Strem Encinitas, California 92024 Name: Brian Strem Email: bstrem@kiorapharma.com Title: President and Chief Executive Officer With a copy to (which shall not constitute notice): Burns & Levinson LLP 125 High Street Boston, MA 02110 Attention: Robert A. Petitt, Esq. Email: rpetitt@burnslev.com [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK. SIGNATURE PAGES FOR PURCHASERS FOLLOW.]

30 [PURCHASER SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT] IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. Name of Purchaser: Signature of Authorized Signatory of Purchaser: Name of Authorized Signatory: Title of Authorized Signatory: Email Address of Authorized Signatory: Address for Notice to Purchaser: Address for Delivery of Warrant Shares to the Purchaser (if not same address for notice): Subscription Amount: $ Shares of Common Stock: Pre-Funded Warrants: Beneficial Ownership Blocker □ 4.99% or □ 9.99% Tranche A Common Warrants: Beneficial Ownership Blocker □ 4.99% or □ 9.99% Tranche B Common Warrants: Beneficial Ownership Blocker □ 4.99% or □ 9.99% EIN Number: [SIGNATURE PAGES CONTINUE]